According to the 12/31/20 ENZC annual disclosure filing (see pages 9 & 10), the "merger" you refer to between ECPO (name later changed to ENZC) and IMMB as proposed in 2017 was TERMINATED on 1/15/2018 and the transfer was done as an ASSET PURCHASE on 3/26/2018 instead. So, IMMB stock was not involved in the transaction. In exchange for the sale IMMB got debt relief, a note receivable and ENZC stock in exchange for the IMMB assets, including the Exclusive License Agreement and all intellectual property associated with the "Patented treatment". This document was signed by ENZC officers and reviewed by their attorney. This is JMHO about what the document says. Below is the quote on Page 10 and a link to the filing, which I believe has been posted here several times in the past.
""On March 26, 2018 an asset purchase agreement was entered with Immunotech Laboratories, Inc whereby the Exclusive License Agreement for the Patented Immunotherapy Treatment for the care of HIV/Aids and Hepatitis C patients, the Forty Nine Percent ownership in Immunotech Laboratories BG, all equipment and licensing of intellectual property associated with the Patented treatment in exchange for a secured note receivable, common stock of Enzolytics, Inc. issued to Immunotech Laboratories, Inc. and assumption of certain debt from Immunotech by Enzolytics, Inc."" https://sec.report/otc/financial-report/270351
News 
Market Data 
Discover 
